A Multi-Center, Placebo-Controlled, Double-Blind, Randomized Trial Comparing the Virologic and Immunologic Activities of 400 Mg Nevirapine in Combination With Zidovudine Versus Zidovudine Alone in Asymptomatic HIV-1 Infected Patients With 4-12 Months of Prior Zidovudine Therapy and 200-500 CD4+ Cell
Not Applicable
Completed
- Conditions
- HIV Infections
- First Posted Date
- 2001-08-31
- Last Posted Date
- 2005-06-24
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 60
- Registration Number
- NCT00002323
- Locations
- ๐บ๐ธ
Johns Hopkins Hosp, Baltimore, Maryland, United States
๐บ๐ธNorthwestern Univ Med School, Chicago, Illinois, United States
๐บ๐ธUniv TX Galveston Med Branch, Galveston, Texas, United States
The Safety and Effectiveness of Nevirapine Plus Nelfinavir in HIV-1 Infected Patients Who Have Taken Stavudine
Phase 1
Completed
- Conditions
- HIV Infections
- First Posted Date
- 2001-08-31
- Last Posted Date
- 2005-06-24
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 24
- Registration Number
- NCT00002381
- Locations
- ๐บ๐ธ
Saint Francis Mem Hosp / HIV Care Unit, San Francisco, California, United States
๐บ๐ธRoger Williams Med Ctr, Providence, Rhode Island, United States
An Open-Label, Staggered Rising Dose Cohort Study Assessing the Pharmacokinetics, Safety, and Tolerance of BI-RG-587 in Combination With Zidovudine in Patients With HIV Infection (CD4+ Cell Count < 400/mm3)
Phase 1
Completed
- Conditions
- HIV Infections
- First Posted Date
- 2001-08-31
- Last Posted Date
- 2008-07-30
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 30
- Registration Number
- NCT00000649
- Locations
- ๐บ๐ธ
Univ of Massachusetts, Worcester, Massachusetts, United States
๐บ๐ธCooper Green Hosp, Birmingham, Alabama, United States
๐บ๐ธUniv of California / San Diego Treatment Ctr, San Diego, California, United States
The Safety and Effectiveness of Nevirapine and Zidovudine, Given Separately and Together, in HIV-1 Infected Patients Who Have No Symptoms of the Disease
Phase 2
Completed
- Conditions
- HIV Infections
- First Posted Date
- 2001-08-31
- Last Posted Date
- 2005-06-24
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 250
- Registration Number
- NCT00002324
- Locations
- ๐บ๐ธ
UCSD Treatment Ctr, San Diego, California, United States
๐บ๐ธSaint Francis Mem Hosp, San Francisco, California, United States
๐บ๐ธUniv of Utah School of Medicine, Salt Lake City, Utah, United States
ยฉ Copyright 2025. All Rights Reserved by MedPath